:572-581. Progressive myoclonus epilepsy (PME) is a syndrome characterized by myoclonic seizures (lightning-like jerks), generalized convulsive seizures, and varying degrees of neurological decline, especially ataxia and dementia. Previously, we characterized three pedigrees of individuals with PME and ataxia, where either clinical features or linkage mapping excluded known PME loci. This report identifies a mutation in PRICKLE1 (also known as RILP for REST/NRSF interacting LIM domain protein) in all three of these pedigrees. The identified PRICKLE1 mutation blocks the PRICKLE1 and REST interaction in vitro and disrupts the normal function of PRICKLE1 in an in vivo zebrafish overexpression system. PRICKLE1 is expressed in brain regions implicated in epilepsy and ataxia in mice and humans, and, to our knowledge, is the first molecule in the noncanonical WNT signaling pathway to be directly implicated in human epilepsy.
orders and Stroke's "Curing Epilepsy 2007" conference established benchmarks to help guide future epilepsy research. Three of these included: 1) the identification of unrecognized causes of epilepsy, 2) the identification of underlying mechanisms of epileptogenesis, and 3) the characterization of comorbidities in people with epilepsy. Further studies of progressive myoclonic epilepsy (PME) syndromes-diseases that confer motor and oftentimes cognitive degeneration-will undoubtedly allow epilepsy researchers to make inroads in all three of these benchmarks. PME syndromes transmit by monogenic inheritance, and thus, the sequencing of the known candidate genes in appropriate patients will help to identify new disease-causing mutations. More importantly, as is reported here by Bassuk et al., genetic mapping of kindreds containing large numbers of affected individuals will identify novel epilepsy genes. Once new PME mutations and genes are identified, investigators then can proceed with studying the biochemical and cellular processes affected by the mutant gene products. Finally, elucidation of these recently identified pathogenic processes will reveal the mechanisms that cause both the seizures and the comorbid motor and cognitive deficits.
In the Bassuk et al. paper, the authors extended the work of three previous papers that independently reported autosomal recessive ataxia epilepsy syndromes in three different Middle Eastern kindreds. In the current study, the authors used linkage mapping, followed by sequencing of all the coding regions and intron-exon boundaries in the linkage area. All patients in the three kindreds possessed a single nucleotide substitution that resulted in a single missense mutation, R104Q, in the so-called PRICKLE1 gene. The authors performed careful controls, revealing that this nucleotide substitution was present neither in any of the 1,054 DNA samples obtained from diverse worldwide populations nor in DNA samples obtained from 300 Middle Eastern control individuals. In addition, the authors found no other variants in the entire PRICKLE1 coding regions among samples provided by another 288 controls. These data strongly suggested that the PRICKLE1 mutation causes this PME syndrome, and that PRICKLE1 represents a novel epilepsy gene.
Before the publication of the paper by Bassuk and colleagues, many epilepsy researchers might have remained blissfully ignorant of PRICKLE1. Clearly, the results of this study give impetus to the elucidation of the wild-type and mutant functions of this novel epilepsy gene. To date, PRICKLE1 has been implicated in two biological functions: 1) a participant in the noncanonical WNT signaling pathway (called "noncanonical" because it acts independently of the of β-catenin transcriptional regulator proteins) and 2) a nuclear translocator receptor for the RE-1 silencing transcription (REST) factor protein.
Prickle was named by Drosophila developmental biologists when they discovered that mutant Prickle proteins produced flies with aberrant patterning of the cuticular hairs, sensory bristles, and eye units (1) . Drosophila Prickle and its vertebrate ortholog, Prickle1, interact with frizzled proteins, which are G-protein-coupled receptors that mediate the Drosophila cell patterning and, in vertebrates, mediate a noncanonical WNT pathway, affecting changes in embryological development.
Overexpression of Prickle1 RNA in zebrafish embryos inhibits a key cellular rearrangement during gastrulation, called convergent extension (2) . To test the effects of mutant Prickle1 on embryogenesis, Bassuk and colleagues injected either wildtype Prickle1 or Prickle1 (R104Q) mRNA into zebrafish embryos and found that Prickle1 (R104Q) conferred significantly smaller effects on convergent extension than wild-type Prickle1. The authors discussed that this finding demonstrated that the R104Q mutation disrupted the in vivo function of Prickle1. It should be emphasized that the gastrulation assay did not imply that the epilepsy associated with PRICKLE1 (R104Q) resulted from impaired embryogenesis. In fact, the patients' clinical and radiographic course argues against macroscopic developmental changes. The R104Q mutation could cause microscopic changes in neuronal network formation, as was demonstrated by the effect of Prickle1 knockdown on neurite outgrowth in neuroblastoma cells (3) . The generation of mice engineered with the Prickle1 (R104Q) mutation and postmortem histopathological analyses of affected patients will determine whether this mutation causes ultrastructural changes in neuronal development.
Apart from its role in the noncanonical WNT signaling pathway, Shimojo and Hersh independently identified Prickle 1 as a nuclear translocator protein that interacts with REST (4, 5) . The R104Q mutation is located in Prickle1's so-called PET domain, a motif of approximately 110 amino acids that is thought to mediate protein-protein interactions. In the present paper, Bassuk et al. demonstrated that that Prickle1 (R104Q) failed to coimmunoprecipitate with REST, which suggests that a possible pathogenic effect of the PRICKLE1 (R104Q) protein is the failure of proper REST translocation.
The consequences of the impaired PRICKLE1 (R104Q)/ REST interaction on REST targeting are in dispute. Shimojo and Hersh demonstrated that heterologous cells overexpressing wild-type Prickle1 localized both Prickle1 and REST to the nucleus, whereas cells expressing various Prickle1 mutations or with knockdown Prickle1 localized REST to the cytoplasm (4, 5) . In contrast, Bassuk et al. demonstrated that wildtype PRICKLE1 colocalized with REST in the cytoplasm, but PRICKLE1 (R104Q) colocalized with REST in the nucleus. Therefore, it is unclear whether, in vivo, PRICKLE1 (R104Q) will enhance or inhibit REST's ability to enter the nucleus to repress the transcription of neuron-specific genes.
The possibility that the PRICKLE1 (R104Q) mutation causes a degenerative epilepsy by modulating REST-mediated inhibition of gene transcription raises the question of whether or not this PME results from cell death and structural changes, or instead, from altered neuronal hyperexcitability or synaptic strength. Many of the genes modulated by REST encode ligandgated and voltage-gated ion channels (6) . Future histopathological studies of patients homozygous for PRICKLE1 (R104Q) and electrophysiological and ultrastructural studies of mice engineered with the prickle1 (R104Q) mutation will reveal what causes this PME. The possibility of altered synaptic strength is particularly intriguing, because it would suggest that therapeutics targeted to ligand-gated and voltage-gated ion channels may be more effective in this PME syndrome than in those associated with structural changes.
In addition to identifying the PRICKLE1 (R104Q) mutation and testing two of its functional consequences, the Bassuk et al. study also phenotypically characterized this novel epilepsy syndrome, including its comorbidities. The patients in all three kindreds experienced a gait ataxia that developed in childhood between ages 4 and 5. The patients then developed myoclonic seizures between ages 5 and 10; the ataxia and myoclonic seizures worsened as the patients grew older. None of the patients experienced impaired cognition. These key features of progressive myoclonic seizures and ataxia in the setting of preserved cognition make this latest PME syndrome very similar to Unverricht-Lundborg disease (epilepsy progressive myoclonic 1 [EPM1]). However, while this syndrome is caused by PRICKLE1, EPM1 is caused by homozygous mutations in cystatin B (CSTB)-a cysteine protease inhibitor that is believed to prevent cell damage form lysosomal proteases. Why would mutant PRICKLE1, a very distinct protein from CSTB, produce a near phenocopy of a CSTB mutation? Moreover, why do PRICKLE1 (R104Q) patients escape MRI evidence of neuronal injury, whereas EPM1 patients possess structural MRI abnormalities (7) , and cstb knock-out mice demonstrate neuronal atrophy and apoptosis (8, 9) ? It is likely that data from further study of the PRICKLE1 (R104Q) patients and the creation of a mouse engineered with the prickle1 (R104Q) mutation will answer these questions and thereby mark further progress toward the achievement of the epilepsy research benchmarks. 
COMMENTARY
T he biological basis of consciousness is a mystery-for centuries, debated by philosophers and neuroscientists alike. In a clinical context, loss of awareness is assumed to require diffuse brain dysfunction, involving either bilateral cerebral hemispheres or the reticular activating system. A notable exception to this rule are patients with temporal lobe epilepsy who may lose consciousness despite clear evidence from EEG and ictal SPECT that the seizures remain localized to one temporal lobe. One promising hypothesis is that focal hippocam-pal seizures can somehow cause a diffuse disruption of cerebral function that may not be apparent on routine scalp EEG. This idea is supported by ictal SPECT imaging studies showing reduced frontal lobe perfusion during temporal lobe seizures with loss of consciousness, but not during seizures with retained awareness (1) . Moreover, intracranial EEG monitoring has shown nonrhythmic, bifrontal, slow activity during temporal lobe seizures (2) . However, while this slowing suggests diffuse cerebral dysfunction, neocortical seizures sometimes can have a similar disorganized appearance, particularly when the recording electrode is not placed immediately adjacent to the seizure focus. In an effort to discover how temporal lobe seizures produce loss of awareness, Englot et al. used a variety of complementary methods in rodent models of epilepsy to argue that The authors build on previous patient and animal studies by defining two distinct electrographic patterns that correspond to specific behavioral seizure types. Using intracranial EEG recordings of rats that were rendered epileptic following pilocarpine-induced status epilepticus, the authors found that all spontaneous seizures began with rhythmic electrical activity in the hippocampus but differed in frontal lobe involvement. Severe behavioral seizures (Racine stage ≥2), with head nodding, forelimb clonus, rearing, and/or falling, were all associated with rhythmic fast electrical activity that spread outside the temporal lobe as they evolved. The authors referred to these events as secondarily generalized seizures. In contrast, partial limbic seizures were defined as more subtle (Racine stage 0 or 1), with behavioral arrest and/or mouth and facial movements associated with irregular bifrontal slow activity. Because the frontal slowing was similar to patterns seen in the postictal phase or during normal sleep, the authors speculated that the activity might represent cerebral dysfunction rather than ictal involvement of the frontal lobes.
In order to explore further the significance of these electrographic changes, a model with more predictable seizures was needed. Toward that end, Englot et al. studied rats that had undergone electrical hippocampal kindling, which has the advantage of allowing predictably evoked hippocampal seizure onset and severity, while at the same time, avoiding the diffuse injury often seen after pilocarpine-induced status epilepticus. As expected, local field potential changes recapitulated the intracranial EEG findings reported in pilocarpine-treated rats. Extracellular multiple-unit activity was measured simultaneously to better assess the activity of individual neurons throughout these events. During a hippocampal seizure, the multiple-unit activity within the hippocampus switched from small individual units to large, rhythmic population spikes, suggesting a somewhat synchronous firing within groups of neurons. A very similar pattern was seen in the multiple-unit activity of the frontal lobes in the course of a secondarily generalized seizure. In contrast, during partial limbic seizures, neuronal firing in the frontal lobes persisted as single units, with periods of reduced firing that were coincident with the slow waves seen in the local field potentials. This firing pattern also was noted to be remarkably similar to the activity present in the postictal state or under deep anesthesia.
While electrophysiological studies allow precise temporal and spatial resolution, those same properties make the techniques prone to spatial undersampling. To assess regional changes in brain function during a seizure, Englot and colleagues performed fMRI imaging in lightly anesthetized/ paralyzed, kindled rats. Secondarily generalized seizures demonstrated increased BOLD signals in a number of areas, including the neocortex, hippocampus, septal area, and thalamus. In contrast, while partial limbic seizures also were associated with increased BOLD signals in many of the same brain regions, there was a distinctly reduced BOLD signal in the frontal cortex that coincided with the areas of electrographic slowing. Increases or decreases in BOLD signals are generally thought to reflect the level of neuronal activity, but this may not always be the case. This interpretation is predicated on the assumption that increased neuronal activity results in increased blood flow beyond that needed for local oxygen consumption, thereby leading to areas of increased blood oxygenation. However, at times, this relationship is otherwise disrupted, possibly because the metabolic demands exceed the vascular capacity (3). Thus, to independently assess blood flow, laser Doppler flow measurements were used to confirm that there was increased frontal perfusion in secondarily generalized seizures but reduced perfusion in partial limbic seizures. By combining the fMRI and laser Doppler flow data, the authors were able to calculate regional changes in oxygen metabolism and found reduced oxygen consumption in the frontal lobes during partial limbic seizures.
The work of Englot et al. strongly suggests that ictal activity in one temporal lobe disrupts frontal lobe function bilaterally. However, the physiological mechanisms underlying these changes remain unknown, and these studies do not completely rule out a possible spread of seizure activity to the frontal lobes. Ictal spread via the midline thalamus has been described in a few animal models of temporal lobe seizures, but usually only in more severe (≥3 Racine stage) limbic seizures (4). Furthermore, while BOLD signal changes by themselves are subject to interpretation, previous work with interictal PET and ictal SPECT suggests a similar distribution of reduced perfusion and metabolism in temporal lobe epilepsy (1) .
A vascular steal of blood flow from the frontal lobes also could explain the imaging findings and electrographic slowing, but it is unlikely for a number of other reasons. First, the two brain regions lie in different vascular territories, and there is sparing of the nearby sensorimotor areas. Second, the changes in local blood flow are actually very small compared with the brain's overall hemodynamic reserve. Furthermore, reduced BOLD signal in the frontal lobes continues to be depressed during the postictal period while temporal lobe hyperperfusion has resolved.
Another possible interpretation for the Englot et al. findings would be some form of synaptically mediated inhibition. While a classical surround inhibition is unlikely, given that nearby sensorimotor and temporal neocortical activities are unaffected, recent anatomical studies have suggested the possibility of more long-range interactions between the mesial temporal lobe and the neocortex. For example, there are direct projections from the subiculum to the anterior thalamus and other rostromedial areas via the fornix (5) . In addition, smaller sets of projections from CA1 to the anterior thalamus (6) as well as directly from CA1 to the retrosplenium, cingulate, and orbital cortex have been described recently (7) . The neurochemical identity of these temporal lobe projections is unknown, so currently it is unclear whether they include inhibitory neurotransmitters or are excitatory fibers with the potential of activating local neocortical inhibitory circuits. Alternatively, projections from the temporal lobe might disrupt the tonic excitation that the cortex normally receives from certain components of the reticular activating system, such as the cholinergic neurons of the basal forebrain or the histaminergic projections from the hypothalamic mammillary bodies (6) .
So, how do these physiologic changes lead to loss of awareness? The answers may lie within the specific cortical regions that are disrupted by temporal lobe seizures in both animal models and patients, primarily the dorsal mesial brain regions in the frontal and parietal lobes, including the mesial frontal, cingulate, precuneus (mesial parietal), and retrosplenium cortices as well as the dorsolateral frontal cortices (8) . These brain regions continuously process both internal and external stimuli, allowing individuals to respond quickly to environment changes in the context of their current physiological and emotional state. These areas have high resting metabolic rates, which are transiently decreased during externally directed attention (9) . Thus, disruption of this default-mode network is thought to interrupt the continuous monitoring of oneself and the environment that subserves normal awareness.
How do changes occurring in temporal lobe seizures compare with those found in other causes of altered awareness, such as absence epilepsy or sleep? Despite different electrographic patterns, both absence and temporal lobe seizures produce very similar fMRI changes, with reduced BOLD signal in the mesial frontal and parietal cortices and/or increased BOLD signal in the thalamus (10, 11) . In contrast, while Englot et al. note that the frontal electrographic activity slowing is similar during temporal lobe seizures and sleep, functional imaging changes seen with sleep are in many ways the opposite of those of partial limbic seizures. Sleep produces increased BOLD and magnetoencephalogram signals in the frontal lobes, along with reduced BOLD signals in the thalamus (11, 12) . So, are the electrographic or perfusion changes telling us anything about the mechanisms for loss of awareness, or are they simply epiphenomena that are specific for each model but unrelated to consciousness, per se? Given the complex network of similarities and differences, it is easy to feel like the proverbial blind man trying to determine the nature of an elephant by only feeling its leg. Part of the problem may involve overly simplistic nomenclature sometimes used in these studies. While it may be convenient to refer to changes in brain function as "activation" or "deactivation," these terms gloss over the fact that a brain region could have an increased electrographic or BOLD activity and still be unable to serve its normal function.
Epilepsy is a network phenomenon that involves dysfunctional activity that spreads to adjacent areas and evolves over time. The work of Englot et al. add another dimension to this issue by reporting that a focal temporal lobe seizure can disrupt bilateral frontal lobe function, without actually spreading to those areas. Their work highlights the fact that, in addition to the temporal and spatial changes, gaining a deeper understanding of epilepsy will require exploring how metabolic/physiological properties spread and evolve during a seizure. Each technique may explore limited aspects of epilepsy, but by combining areas of expertise, it may be possible to begin to comprehend the true nature of the beast. While these seemingly disparate studies may seem to compare apples and oranges, perhaps investigators are closer to comparing trunks and tails.
by Andre H. Lagrange, MD, PhD B ecause of the brain's complexity, it can be a daunting task to choose a new investigative approach to epileptogenic mechanisms. Mutations that cause epilepsy with high penetrance provide a solid starting point for laboratory investigation. Dibbens et al. offer compelling evidence that disruption of protocadherin 19, a member of the cadherin superfamily, causes epileptogenesis and developmental regression during infancy. This finding is exciting and propitious. It opens a very new angle on epileptogenesis and allows epilepsy researchers to leverage a great amount of existing knowledge of cadherin biology.
Epilepsy and mental retardation limited to females (EFMR) was first described in a single, large family in 1971 and has remained a clinical rarity. However, EFMR may be more common than previously thought. As recently suggested by Scheffer et al., the disorder's nearly unique, male-sparing pattern and varied expression in females make it easily overlooked in small families (1) . Most affected females appear normal through early infancy. However, convulsions begin between 6 and 36 months (mean, 12 months) of age. Developmental regression of variable severity occurs in about half of patients, either coincidentally with seizure onset or within 1 to 2 years after it. Initial seizures often are precipitated by febrile illness. Seizures without such provocation continue into later life. Patients experience a variety of generalized and focal seizure types; in a slight majority of cases, these eventually remit between 6 and 24 years (mean, 12 years) of age. Intellectual disability generally persists after seizure remission, however. Although brain MRIs of several patients reviewed by Scheffer et al. showed no structural abnormality, neuropathological studies on a single patient treated surgically for focal seizures revealed cortical dysplasia (2) . Penetrance is high: of 68 mutation-bearing females now identified by Dibbens et al., only two were classified as clinically unaffected. Male carriers of the EFMR gene, though spared epilepsy and significant cognitive disability, may have obsessive personality traits (1) . Linkage analysis narrowed the EFMR locus to an approximately 34-megabase region of the X chromosome (1, 2) . However, this interval still contained several hundred genes.
Rather than taking the usual approach of further chromosomal mapping and sequencing of individual candidate genes, Dibbens et al. used "resequencing," a rapidly evolving Epilepsy Currents, Vol. 9, No. 3 (May/June) 2009 pp. 87-89 Wiley Periodicals, Inc. C American Epilepsy Society combination of computerized data analysis (i.e., informatics) and fast, low-cost DNA sequencing technology, to identify protocadherin 19 as the gene mutated in EFMR (3) . First, the authors used the Sanger Institute's vertebrate genome annotation (Vega) database to identify all genes near the EFMR locus (4). They next performed automated sequencing on 737 genes from the probands of three EFMR families. This impressive effort revealed only a single base substitution mutation in protocadherin 19 from one patient! Although the other probands' protocadherin 19 sequences initially appeared completely normal, further bioinformatic sleuthing indicated that the protocadherin 19 sequence, as listed in the Vega database, might lack portions of the gene's functionally essential first exon. Sequencing the DNA of the predicted complete first exon revealed protocadherin 19 mutations in affected females and carrier males from all seven families studied. Thus, iron-clad genetic evidence now links protocadherin 19 to a form of epilepsy with a distinctive and carefully analyzed developmental profile.
Protocadherin 19 has not been well studied but shares basic structural and functional features with other cadherins (5-7), including a molecular plan consisting of an extracellular domain that mediates cell-cell interactions, a short segment crossing the plasma membrane, and a cytoplasmic domain that anchors to the cytoskeleton and integrates with intracellular signal transduction pathways. In the best-studied cadherins (called the classical cadherins), the extracellular domain extends from the membrane and displays a combination of protruding bumps and hydrophobic pockets along one surface. These bumps and pockets can interlock in an antiparallel zipper-like fashion with an identical cadherin on an adjoining cell. Such cadherin-based adhesion is present at adherens junctions of epithelia, between fasciculated axons, and across synapses. Furthermore, there are multiple related cadherins, each of which adheres preferentially to their own type, thus providing a mechanism for cell sorting and morphogenesis during development. Finally, the stability of classical cadherin adhesion depends on the extracellular Ca 2+ ion concentration, and changes in cadherin binding have been implicated as activity-dependent regulators of synaptic shape and efficacy.
The cadherins are an extremely large gene superfamily. Of the over 100 human cadherin-related genes, about 70 are members of the protocadherin subgroup. Protocadherins possess extracellular domains that are homologous to those of classical cadherins and novel intracellular domains. Although the name protocadherin implies an early evolutionary origin to these genes, the opposite is true. Protocadherins are absent in invertebrates, such as flies and worms, and only began to appear in basal chordates, the immediate predecessors of vertebrates. A spectacular expansion in protocadherin gene diversity occurred in the earliest vertebrates. All the protocadherin genes are predominantly expressed in the brain. Indeed, it has been suggested that this protocadherin expansion may be essential for the elaborate plan and sophisticated circuitry of the vertebrate brain (7) . About 50 protocadherins, derived from a single ancestor, have been maintained throughout vertebrate evolution as an extraordinarily large gene cluster (8) . These clustered protocadherins, located on chromosome 5 in humans and chromosome 18 in mice, are divided into α, β, and γ subgroups. The 20 or so remaining protocadherins, notably including protocadherin 19, are distributed among the other chromosomes and thus are termed nonclustered or δ protocadherins.
Although protocadherins have been subjected to relatively few functional studies, this work already has revealed significant differences compared with the classical cadherins. The extracellular domains of some α and γ protocadherin seem to lack the ability to form strong adhesive bonds between neighboring cells, but instead, combine on the surface of the same cell, as heterodimeric proteins (6) . In cerebellar Purkinje cells, individual cells express distinct combinations of such α and γ protocadherin pairs, which may provide a combinatorial bar code capable of uniquely identifying cell subclasses (6) . Consistent with that idea, a number of protocadherin proteins have been localized to synapses using immunohistochemistry (9) . Gene knock-out studies show that different protocadherins are required for normal axon tract formation by particular cell types, including protocadherin 7 for retinal ganglion cells and protocadherin 10 for striatal and thalamocortical neurons (10, 11) . After knockout of the entire γ protocadherin cluster, spinal motoneurons are born, migrate, extend axons, and begin to form synapses and then undergo dramatic apoptosis. If apoptotic paths are blocked, the neurons survive, but mice lack spinal cord synapses and are nearly immobile (12) . Thus, protocadherins appear quite important for circuits and synapses.
By linking protocadherin 19 and EFMR in a convincing manner, Scheffer et al. (1) and Dibbens et al. have provided both a solid rationale for focused mechanistic studies and a new class of candidates for genetic screening. Future experiments will likely include an analysis of the extracellular and intracellular protein-protein interactions, cell-type and developmental stage-specific expression, and neuronal subcellular localization of protocadherin 19 and its closest cadherin family relatives. Such work may illuminate the basis for the curious male-sparing pattern in EFMR and reveal how generally important cadherin superfamily disruptions are for human epileptogenesis and cognition dysfunction.
by Edward C. Cooper, MD, PhD
